Education
About Us
Working with TipRanks
Follow Us
Nuformix Plc (GB:NFX)
LSE:NFX
NFX Stock Chart & Stats
Day’s Range― - ―
52-Week Range0.04p - 0.30p
Previous CloseN/A
Volume1.00M
Average Volume (3M)32.48M
Market Cap
£1.80M
Enterprise Value1.88M
Total Cash (Recent Filing)£20.21K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.39
Next Earnings
Dec 16, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,995,709,400
10 Day Avg. Volume38,524,074
30 Day Avg. Volume32,484,997
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)1.08
Price to Sales (P/S)0.00
P/FCF Ratio-5.71K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Nuformix Plc News
PremiumCompany Announcements
Nuformix Confirms Total Voting Rights Following Share Issuance
PremiumCompany Announcements
Nuformix Secures European Orphan Drug Designation for NXP002 in IPF
PremiumCompany Announcements
Nuformix plc Announces Prospectus for New Share Issuance
PremiumCompany Announcements
Nuformix Announces £210,000 Placing to Advance Fibrosis Treatment Program
PremiumCompany Announcements
Nuformix Showcases Promising NXP002 Data at ATS Congress 2025
PremiumCompany Announcements
Nuformix Reports Progress on NXP002 and Financial Results for H1 2025
PremiumCompany Announcements
Nuformix’s NXP002 Receives Positive EMA Opinion for Orphan Drug DesignationOptions Prices
Currently, No data available
---
Ownership Overview
4.71% Insiders
―
Mutual Funds
― Other Institutional Investors
95.29% Public Companies and
Individual Investors
NFX FAQ
What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest share price was 0.04p and its highest was 0.30p in the past 12 months.
What is Nuformix Plc’s market cap?
Nuformix Plc’s market cap is £1.80M.
When is Nuformix Plc’s upcoming earnings report date?
Nuformix Plc’s upcoming earnings report date is Dec 16, 2025 which is in 151 days.
How were Nuformix Plc’s earnings last quarter?
Currently, no data Available
Is Nuformix Plc overvalued?
According to Wall Street analysts Nuformix Plc’s price is currently Overvalued.
Does Nuformix Plc pay dividends?
Nuformix Plc does not currently pay dividends.
What is Nuformix Plc’s EPS estimate?
Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuformix Plc have?
Nuformix Plc has 1,995,709,400 shares outstanding.
What happened to Nuformix Plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nuformix Plc?
Currently, no hedge funds are holding shares in GB:NFX
Company Description
Nuformix Plc
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Technical Analysis
Evgen Pharma
―
Oncimmune Holdings
―
Cizzle Biotechnology Holdings PLC
―
ValiRx plc
―
Roquefort Investments PLC
―